• Company
• 'Padcev+Keytruda' combination therapy is set to land in KOR
• by Eo, Yun-Ho Jul 25, 2024 05:51am

• Opinion
• [Reporter's View] Keeping up with the Chinese bio industry
• by Son, Hyung-Min Jul 24, 2024 05:51am

• Policy
• Gvt commences 'Machine Learning AI Project' for new drug dev
• by Lee, Jeong-Hwan Jul 24, 2024 05:51am

• Policy
• Roche’s Phesgo is applied RSA for reimb in Korea
• by Lee, Tak-Sun Jul 24, 2024 05:51am

• Company
• Samsung Bioepis’ Soliris biosimilar is approved in the U.S.
• by Chon, Seung-Hyun Jul 24, 2024 05:51am

• Company
• Reimb applied for new HIV drug 'Vocabria+Rekambys'
• by Eo, Yun-Ho Jul 24, 2024 05:50am

• Company
• Will 'Zejula' be reimbursed for HRD-positive ovarian cancer?
• by Eo, Yun-Ho Jul 23, 2024 05:48am

• Company
• Opdivo approved as 1st-line Tx for urothelial cell carcinoma
• by Hwang, Byung-woo Jul 23, 2024 05:48am

• Company
• "Trodelvy gives new hope for triple-negative breast cancer"
• by Son, Hyung-Min Jul 23, 2024 05:48am

• Company
• Eisai reports degrowth for 3 consecutive years
• by Hwang, Byung-woo Jul 23, 2024 05:47am